Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 5, 2012, Pages 1155-1163

  Krogh Madsen, Mikkel ^a   Bender, Brendan ^b   Jensen, Morten Krogh ^c   Nielsen, Ove Juul ^d   Friberg, Lena E ^b   Honoré, Per Hartvig ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UPPSALA UNIVERSITY   (Sweden)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d University of Copenhagen   (Denmark)

Author keywords

Acute myeloid leukemia; Cytarabine; Daunorubicin; Etoposide; NONMEM; Population pharmacokinetics

Indexed keywords

CREATININE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; BIOLOGICAL MODEL; BLOOD; BODY SURFACE; CLINICAL TRIAL; DOSE RESPONSE; MIDDLE AGED; NONLINEAR SYSTEM; PATHOLOGY; TISSUE DISTRIBUTION; URINE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY SURFACE AREA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CREATININE; CYTARABINE; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PROSPECTIVE STUDIES; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84862290299     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1800-z     Document Type: Article

References (38)

1. Estey E, Dohner H (2006) Acute myeloid leukaemia. Lancet 368(9550):1894-1907 (Pubitemid 44794525)
2. Burnett A, Wetzler M, Lowenberg B (2011) Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29(5):487-494
3. Cros E, Jordheim L, Dumontet C, Galmarini CM (2004) Problems related to resistance to cytarabine in acute myeloid leukemia. Leuk Lymphoma 45(6):1123-1132 (Pubitemid 38584893)
4. Hiddemann W (1991) Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens. Ann Hematol 62(4):119-128
5. Chabner BA, Ryan DP, Paz-Ares L, Garcia-Carbonero R, Calabresi P (2001) Antineoplastic Agents. In: Hardman JG, Limbird LE, Gilman AG (eds) The pharmacological basis of therapeutics, 10th edn. McGraw-Hill, New York, pp 1389-1460
6. Hande KR (1998) Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34(10):1514-1521 (Pubitemid 28446331)
7. Rabbani A, Finn RM, Ausio J (2005) The anthracycline antibiotics: antitumor drugs that alter chromatin structure. Bioessays 27(1):50-56 (Pubitemid 40128622)
8. Richardson DS, Johnson SA (1997) Anthracyclines in haematology: preclinical studies, toxicity and delivery systems. Blood Rev 11(4):201-223 (Pubitemid 28045205)
9. Robert J, Gianni L (1993) Pharmacokinetics and metabolism of anthracyclines. Cancer Surv 17:219-252
10. Robert J (2005) Anthracyclines. In: Schellens JH, McLeod H, Newell DR (eds) Cancer Clinical Pharmacology, 1st edn. Oxford University Press, Oxford, pp 117-133
11. Bogason A, Quartino AL, Lafolie P et al (2011) Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia. Br J Clin Pharmacol 71(4):514-521
12. Fleming RA, Capizzi RL, Rosner GL et al (1995) Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study. Cancer Chemother Pharmacol 36(5):425-430
13. Burk M, Heyll A, Arning M, Volmer M, Fartash K, Schneider W (1997) Pharmacokinetics of high-dose cytarabine and its deamination product-a reappraisal. Leuk Lymphoma 27(3-4):321-327 (Pubitemid 27501191)
14. You B, Tranchand B, Girard P et al (2008) Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. Lung Cancer 62(2):261-272
15. Nguyen L, Chatelut E, Chevreau C et al (1998) Population pharmacokinetics of total and unbound etoposide. Cancer Chemother Pharmacol 41(2):125-132 (Pubitemid 28096266)
16. Wilde S, Jetter A, Rietbrock S et al (2007) Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity. Clin Pharmacokinet 46(4):319-333 (Pubitemid 46507010)
17. Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28(5):481-504 (Pubitemid 33151426)
18. Gisleskog PO, Karlsson MO, Beal SL (2002) Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn 29(5-6):473-505
19. Krogh-Madsen M, Hansen SH, Honore PH (2010) Simultaneous determination of cytosine arabinoside, daunorubicin and etoposide in human plasma. J Chromatogr B Anal Technol Biomed Life Sci 878(22):1967-1972
20. Ahn JE, Karlsson MO, Dunne A, Ludden TM (2008) Likelihood based approaches to handling data below the quantification limit usingNONMEMVI. J Pharmacokinet Pharmacodyn 35(4):401-421
21. Bergstrand M, Karlsson MO (2009) Handling data below the limit of quantification in mixed effect models. AAPS J 11(2): 371-380
22. Bonate PL (2006) Pharmacokinetic-pharmacodynamic modeling and simulation. Springer, New York
23. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31-41
24. Kroschinsky FP, Friedrichsen K, Mueller J et al (2008) Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. Cancer Chemother Pharmacol 61(5):785-790 (Pubitemid 351302034)
25. Burgio DE, Gosland MP (1998) McNamara a. Effects of P-glycoprotein modulators on etoposide elimination and central nervous system distribution. J Pharmacol Exp Ther 287(3):911-917 (Pubitemid 29131600)
26. Rustum YM, Raymakers RA (1992) 1-Beta-arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview. Pharmacol Ther 56(3):307-321 (Pubitemid 23096374)
27. Andersson B, Beran M, Peterson C, Tribukait B (1982) Significance of cellular pharmacokinetics for the cytotoxic effects of daunorubicin. Cancer Res 42(1):178-183 (Pubitemid 12207267)
28. van den Bongard HJ, Mathot RA, Beijnen JH, Schellens JH (2000) Pharmacokinetically guided administration of chemotherapeutic agents. Clin Pharmacokinet 39(5):345-367
29. Panteghini M, Myers GL, Miller WG, Greenberg N (2006) The importance of metrological traceability on the validity of creatinine measurement as an index of renal function. Clin Chem Lab Med 44(10):1287-1292
30. Kirkpatrick CM, Duffull SB, Begg EJ (1999) Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. Br J Clin Pharmacol 47(6):637-643 (Pubitemid 29257661)
31. Fesler P, Mimran A (2011) Estimation of glomerular filtration rate: what are the pitfalls? Curr Hypertens Rep 13(2):116-121
32. Salgado JV, Neves FA, Bastos MG et al (2010) Monitoring renal function: measured and estimated glomerular filtration rates-a review. Braz J Med Biol Res 43(6):528-536
33. Mould DR, Holford NH, Schellens JH et al (2002) Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther 71(5):334-348 (Pubitemid 34518144)
34. McLeod HL, Evans WE (1993) Clinical pharmacokinetics and pharmacodynamics of epipodophyllotoxins. Cancer Surv 17:253-268
35. Hartmann JT, Lipp HP (2006) Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II-mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf 29(3):209-230 (Pubitemid 43363834)
36. Kaul S, Srinivas NR, Mummaneni V, Igwemezie LN, Barbhaiya RH (1996) Effects of gender, age, and race on the pharmacokinetics of etoposide after intravenous administration of etoposide phosphate in cancer patients. Semin Oncol 23(6 Suppl 13):23-29 (Pubitemid 27030446)
37. [webA] AML 17 trial protocol: ; Accessed July 15, 2011
38. [webB] AML 15 trial protocol: http://www.download.bham.ac.uk/bctu/AML15/ Amendment%20Nov%202007/ AML15%20protocol%20version%207%20Final%20200704201%20with%20no%20track%20change s.pdf; Accessed July 15, 2011